Fennec Pharmaceuticals Inc.

NasdaqCM FENC

Fennec Pharmaceuticals Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024: 93.50%

Fennec Pharmaceuticals Inc. Gross Profit Margin is 93.50% for the Trailing 12 Months (TTM) ending September 30, 2024, a -1.52% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Fennec Pharmaceuticals Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was 94.94%.
Fennec Pharmaceuticals Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was 100.00%.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqCM: FENC

Fennec Pharmaceuticals Inc.

CEO	Mr. Rostislav Raykov
IPO Date	Sept. 15, 2017
Location	United States
Headquarters	68 TW Alexander Drive
Employees	29
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Key trends

Past 5 years